CLINICAL STUDY: ADJUNCTIVE THERAPY AND PCI
Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention
Albert W. Chan, MD, MS, FRCP(C)*,
Martin J. Quinn, MD, PhD*,
Deepak L. Bhatt, MD*,
Derek P. Chew, MBBS, FRCP(A)*,
David J. Moliterno, MD, FACC*,
Eric J. Topol, MD, FACC* and
Stephen G. Ellis, MD, FACC*,*
* Section of Interventional Cardiology, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Manuscript received December 30, 2001;
revised manuscript received April 12, 2002,
accepted May 15, 2002.
* Reprint requests and correspondence: Dr. Stephen G. Ellis, Sones Cardiac Catheterization Laboratories, The Cleveland Clinic Foundation, 9500 Euclid Avenue, F25, Cleveland, Ohio 44195, USA. elliss{at}ccf.org
OBJECTIVES: The goal of this study was to evaluate the mortality benefit of beta-blockers after successful percutaneous coronary intervention (PCI).
BACKGROUND: Beta-blockers reduce mortality after myocardial infarction (MI), though limited data are available regarding their role after successful PCI.
METHODS: Each year from 1993 through 1999, the first 1,000 consecutive patients undergoing PCI were systematically followed up. Patients presenting with acute or recent MI, shock, or unsuccessful revascularization procedures were excluded from the analysis. Clinical, procedural, and follow-up data of beta-blocker-treated and non-beta-blocker-treated patients were compared. A multivariate survival analysis model using propensity analysis was used to adjust for heterogeneity between the two groups.
RESULTS: Of the 4,553 patients, 2,056 (45%) were treated with beta-blockers at the time of the procedure. Beta-blocker therapy was associated with a mortality reduction from 1.3% to 0.8% at 30 days (p = 0.13) and a reduction from 6.0% to 3.9% at one year (p = 0.0014). This survival benefit of beta-blockers was independent of left ventricular function, diabetic status, history of hypertension, or history of MI. Using propensity analysis, beta-blocker therapy remained an independent predictor for one-year survival after PCI (hazard ratio, 0.63; 95% confidence interval, 0.46 to 0.87; p = 0.0054).
CONCLUSIONS: Within this large prospective registry, beta-blocker use was associated with a marked long-term survival benefit among patients undergoing successful elective percutaneous coronary revascularization.
|
Abbreviations and Acronyms
| | ACE | | angiotensin-coverting enzyme | | CABG | | coronary artery bypass grafting | | CAD | | coronary artery disease | | CI | | confidence interval | | CK | | creatine kinase | | COPD | | chronic obstructive pulmonary disease | | LVEF | | left ventricular ejection fraction | | MI | | myocardial infarction | | PCI | | percutaneous coronary intervention |
|
This article has been cited by other articles:

|
 |

|
 |
 
L. Venkitachalam, K. E. Kip, F. Selzer, R. L. Wilensky, J. Slater, S. R. Mulukutla, O. C. Marroquin, P. C. Block, D. O. Williams, S. F. Kelsey, et al.
Twenty-Year Evolution of Percutaneous Coronary Intervention and Its Impact on Clinical Outcomes: A Report From the National Heart, Lung, and Blood Institute-Sponsored, Multicenter 1985-1986 PTCA and 1997-2006 Dynamic Registries
Circ Cardiovasc Intervent,
February 1, 2009;
2(1):
6 - 13.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Ibanez, S. Prat-Gonzalez, W. S. Speidl, G. Vilahur, A. Pinero, G. Cimmino, M. J. Garcia, V. Fuster, J. Sanz, and J. J. Badimon
Early Metoprolol Administration Before Coronary Reperfusion Results in Increased Myocardial Salvage: Analysis of Ischemic Myocardium at Risk Using Cardiac Magnetic Resonance
Circulation,
June 12, 2007;
115(23):
2909 - 2916.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Atar, M. E. Korkmaz, I. A. Atar, O. Gulmez, B. Ozin, H. Bozbas, T. Erol, A. Aydinalp, A. Yildirir, M. Yucel, et al.
Effects of metoprolol therapy on cardiac troponin-I levels after elective percutaneous coronary interventions
Eur. Heart J.,
March 1, 2006;
27(5):
547 - 552.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Herrmann
Peri-procedural myocardial injury: 2005 update
Eur. Heart J.,
December 1, 2005;
26(23):
2493 - 2519.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. A. Jaber, R. J. Lennon, V. Mathew, D. R. Holmes Jr, A. Lerman, and C. S. Rihal
Application of Evidence-Based Medical Therapy Is Associated With Improved Outcomes After Percutaneous Coronary Intervention and Is a Valid Quality Indicator
J. Am. Coll. Cardiol.,
October 18, 2005;
46(8):
1473 - 1478.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. P. Faxon
Beta-blocker therapy and primary angioplasty: What is the controversy?
J. Am. Coll. Cardiol.,
May 19, 2004;
43(10):
1788 - 1790.
[Full Text]
[PDF]
|
 |
|
|